NAD recommends additional clarification in Lamisil ads
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Wednesday recommended Novartis Consumer Health to modify advertising claims for its Lamisil AT Gel Advanced athlete’s foot treatment, asking that it add the phrase “between the toes” to its claim of eradicating athlete’s foot, so as to avoid the assumption that it clears athlete’s foot on the whole foot.
In addition, NAD recommended that in future advertising, Novartis “clearly disclose that the object of the comparison [between Lamisil AT Gel] is Lamisil AT Cream” in making its claims of faster absorption, the division stated. And NAD recommended that claim be modified to avoid conveying the message that consumers will experience more rapid relief with more rapid absorption.
In its advertiser’s statement, Novartis disagreed with the NAD findings, but agreed to make the modifications in future advertisements.
The challenge was sponsored by Schering-Plough, which markets rival athlete’s foot remedy Lotrimin.
Study shows only strict compliance to ginko biloba regimen has effect
BALTIMORE Neurology, the official journal of the American Academy of Neurology, on Wednesday published a study that found that ginkgo biloba extract neither altered the risk of progression from normal to clinical dementia rating, nor protected against a decline in memory function unless those supplementing with gingko were strictly compliant with a regimen of gingko.
In addition, more stroke and transient ischaemic attacks were observed among the group supplementing with ginkgo biloba, which may necessitate further study to confirm the findings, study authors suggested.
The randomized, placebo-controlled, double-blind, 42-month pilot study was conducted in 188 cognitively-intact subjects 85 and older. The amount of ginkgo used to supplement was not disclosed in the published abstract.
In a secondary analysis, where study authors controlled the medication adherence level, the group supplementing with gingko did have a lower risk of progression from normal to clinical dementia rating, and a smaller decline in memory scores.
“Results of larger prevention trials taking into account medication adherence may clarify the effectiveness of [gingko supplementation],” study authors concluded. “[And] more stroke and TIA cases observed among the GBE group requires further study to confirm.”
Tahitian Noni Juice with Acerola available in limited edition
PROVO, Utah Tahitian Noni International, on Thursday announced the availability of a limited edition super fruit blend of Tahitian Noni Juice with Acerola, a juice that combines the benefits of noni with Acerola for an immune boost.
“Tahitian Noni Juice is the No. 1 selling noni-juice product in the world,” stated Shon Whitney, vice president of marketing for Tahitian Noni International. “This new flavor addition will give people the refreshing taste of Acerola and provide another reason to drink Tahitian Noni Juice for those who are looking for a high source of natural vitamin C.”